Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis via inducing cell cycle arrest and apoptosis

Figure 1 Ubiquitin-conjugating enzyme E2T is overexpressed in hepatocellular carcinoma. A and B: The relative expression of ubiquitin-conjugating enzyme E2T (UBE2T) in hepatocellular carcinoma (HCC) and adjacent normal tissues based on The Cancer Genome Atlas (TCGA) database (fold change =11.083, n = 50, P = 2.14E-63); C: UBE2T mRNA expression in HCC (n = 373) and normal (n = 169) tissues based on the TCGA database. P < 0.001; D: The overall survival of HCC patients who were divided into the UBE2T high expression group (n = 186) and the UBE2T low expression group (n = 187). P = 0.012. FC: Fold change; TCGA: The Cancer Genome Atlas.